Perioperative management of ileocecal Crohn’s disease in the current era

References

• Higgens CS, Allan RN. Crohn’s disease of the distal ileum. Gut. 1980;21(11):933–940.
   PubMed Web of Science ®Google Scholar
• Cooke WT, Mallas E, Prior P, et al. Crohn’s disease: course, treatment and long term prognosis. Q J Med. 1980;49(195):363–384.
   PubMedGoogle Scholar
• D’Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667.
   PubMed Web of Science ®Google Scholar
• Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020;69(2):274-282.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Loftus EV Jr., Ng SC, et al. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61:622–629.
   PubMed Web of Science ®Google Scholar
• Brouquet A, Maggiori L, Zerbib P, GETAID chirurgie group, et al. Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort. Ann Surg. 2018;267(2):221–228.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Umegae S, et al. Impact of preoperative nutritional status on the incidence rate of surgical complications in patients with inflammatory bowel disease with vs without preoperative biologic therapy: a case-control study. Clin Transl Gastroenterol. 2019;10(6):e00050.
   PubMedGoogle Scholar
• De Cruz P, Kamm MA, Prideaux L, et al. Postoperative recurrent luminal Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2012;18(4):758–777.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Watanabe T. Strategies for the prevention of postoperative recurrence of Crohn’s disease. Colorectal Dis. 2013;15(12):1471–1480.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Teixeira FV, Saad-Hossne R, et al. Anti-TNF and postoperative complications in abdominal Crohn’s disease surgery. Curr Drug Targets. 2019;20(13):1339–1348.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179–1207.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
   PubMed Web of Science ®Google Scholar
• Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on surgery for Crohn’s disease. J Crohns Colitis. 2018;12(1):1–16.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 14(1): 4–22. 2020.
   PubMed Web of Science ®Google Scholar
• Kotze PG, Ma C, Almutairdi A, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(6):626–637.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg. 2000;87(12):1697–1701.
   PubMed Web of Science ®Google Scholar
• Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020;69(2):274–282.
   PubMed Web of Science ®Google Scholar
• Iesalnieks I, Kilger A, Glass H, et al. Perforating Crohn’s ileitis: delay of surgery is associated with inferior postoperative outcome. Inflamm Bowel Dis. 2010;16(12):2125–2130.
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2(11): 785–792. 2017.
   PubMed Web of Science ®Google Scholar
• Klag T, Wehkamp J, Goetz M. Endoscopic balloon dilation for Crohn’s disease-associated strictures. Clin Endosc. 2017;50(5):429–436.
   PubMed Web of Science ®Google Scholar
• Shen B, Kochhar G, Navaneethan U, et al. Practical guidelines on endoscopic treatment for Crohn’s disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020;5(4):393–405.
   PubMed Web of Science ®Google Scholar
• Agarwala R, Singh AK, Shah J, et al. Ileocecal thickening: clinical approach to a common problem. JGH Open. 2019;3(6):456–463.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–260.
   PubMed Web of Science ®Google Scholar
• Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol. 2008;103(9):2373–2381.
   PubMed Web of Science ®Google Scholar
• Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320–327.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–883.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(12):2404–2413.
   PubMed Web of Science ®Google Scholar
• Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008;12(10):1738–1744.
   PubMed Web of Science ®Google Scholar
• Mascarenhas C, Nunoo R, Asgeirsson T, et al. Outcomes of ileocolic resection and right hemicolectomies for Crohn’s patients in comparison with non-Crohn’s patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications. Am J Surg. 2012;203(3):375–378.
   PubMed Web of Science ®Google Scholar
• Serradori T, Germain A, Scherrer ML, et al. The effect of immune therapy on surgical site infection following Crohn’s Disease resection. Br J Surg. 2013;100(8):1089–1093.
   PubMed Web of Science ®Google Scholar
• Morar PS, Hodgkinson JD, Thalayasingam S, et al. Determining predictors for intra-abdominal septic complications following ileocolonic resection for Crohn’s disease-considerations in pre-operative and peri-operative optimisation techniques to improve outcome. J Crohns Colitis. 2015;9(6):483–491.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Spinelli A, Suzuki Y, et al. Risk factors for complications after ileocolonic resection for Crohn’s disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United European Gastroenterol J. 2016;4(6):784–793.
   PubMed Web of Science ®Google Scholar
• Fumery M, Seksik P, Auzolle C, et al. Postoperative complications after ileocecal resection in Crohn’s disease: a prospective study from the REMIND Group. Am J Gastroenterol. 2017;112(2):337–345.
   PubMed Web of Science ®Google Scholar
• de Buck van Overstraeten A, Eshuis EJ, Vermeire S, et al. Short- and medium-term outcomes following primary ileocaecal resection for Crohn’s disease in two specialist centres. Br J Surg. 2017 Nov;104(12):1713–1722.
   PubMed Web of Science ®Google Scholar
• Lightner AL, Raffals LE, Mathis KL, et al. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis. 2017;11(2):185–190.
   PubMed Web of Science ®Google Scholar
• Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol. 2017;112(9):1423–1429.
   PubMed Web of Science ®Google Scholar
• Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in vedolizumab-treated Crohn’s disease patients undergoing major abdominal operations. Aliment Pharmacol Ther. 2018;47(5):573–580.
   PubMed Web of Science ®Google Scholar
• Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohns Colitis. 2018;12(4):402–407.
   PubMed Web of Science ®Google Scholar
• Novello M, Stocchi L, Holubar S, et al. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis. Int J Colorectal Dis. 2019;34(3):451–457.
   PubMed Web of Science ®Google Scholar
• Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFa therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261(3):487–496.
   PubMed Web of Science ®Google Scholar
• Cohen BL, Fleshner P, Kane SV, et al. Prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for post-operative injection. Gastroenterology. 156(Suppl 1): S–80. 2019.
   Google Scholar
• Mijac DD, Jankovic GL, Jorga J, et al. Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med. 2010;21(4):315–319.
   PubMed Web of Science ®Google Scholar
• Goh J, O’Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17(3):307–320.
   PubMed Web of Science ®Google Scholar
• Jacobson S. Early postoperative complications in patients with Crohn’s disease given and not given preoperative total parenteral nutrition. Scand J Gastroenterol. 2012;47(2):170–177.
   PubMed Web of Science ®Google Scholar
• Grass F, Pache B, Martin D, et al. Preoperative nutritional conditioning of Crohn’s patients-systematic review of current evidence and practice. Nutrients. 2017;9(6):pii:E562.
   Web of Science ®Google Scholar
• Li Y, Zuo L, Zhu W, et al. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn’s disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94(5):e478.
   PubMed Web of Science ®Google Scholar
• Heerasing N, Thompson B, Hendy P, et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(5):660–669.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nakahigashi M, Shimoyama T, et al. Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn’s disease? A case-matched study. Colorectal Dis. 2020;22(5):554–561.
   PubMed Web of Science ®Google Scholar
• Volkert D, Berner YN, Berry E, DGEM (German Society for Nutritional Medicine), Lenzen-Grossimlinghaus R, Krys U, Pirlich M, et al.; ESPEN (European Society for Parenteral and Enteral Nutrition), et al. ESPEN guidelines on enteral nutrition: geriatrics. Clin Nutr. 2006;25(2):330–360.
   PubMed Web of Science ®Google Scholar
• Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(10):953–962.
   PubMed Web of Science ®Google Scholar
• Ali F, Al-Kindi SG, Blank JJ, et al. Elevated venous thromboembolism risk following colectomy for IBD is equal to those for colorectal cancer for ninety days after surgery. Dis Colon Rectum. 2018;61(3):375–381.
   PubMed Web of Science ®Google Scholar
• Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60(1):61–67.
   PubMed Web of Science ®Google Scholar
• Gross ME, Vogler SA, Mone MC, et al. The importance of extended postoperative venous thromboembolism prophylaxis in IBD: a National Surgical Quality Improvement Program analysis. Dis Colon Rectum. 2014;57(4):482–489.
   PubMed Web of Science ®Google Scholar
• McKenna NP, Behm KT, Ubl DS, et al. Analysis of postoperative venous thromboembolism in patients with chronic ulcerative colitis: is it the disease or the operation? Dis Colon Rectum. 2017;60(7):714–722.
   PubMed Web of Science ®Google Scholar
• Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e227S–e277S.
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6):381S–453S.
   PubMed Web of Science ®Google Scholar
• Wilson MZ, Connelly TM, Tinsley A, et al. Ulcerative colitis is associated with an increased risk of venous thromboembolism in the postoperative period: the results of a matched cohort analysis. Ann Surg. 2015;261(6):1160–1166.
   PubMed Web of Science ®Google Scholar
• Fleming FJ, Aquina CT. Extended-duration venous thromboembolism prophylaxis following colorectal surgery: ready for prime time? Dis Colon Rectum. 2018;61(3):273–274.
   PubMed Web of Science ®Google Scholar
• Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717–725.
   PubMed Web of Science ®Google Scholar
• Rozich NS, Landmann A, Butler CS, et al. Tobacco smoking associated with increased anastomotic disruption following pancreaticoduodenectomy. J Surg Res. 2019;233:199–206.
   PubMed Web of Science ®Google Scholar
• Kulaylat AS, Kulaylat AN, Schaefer EW, et al. Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis. JAMA Surg. 2017;152(8):e171538.
   PubMed Web of Science ®Google Scholar
• Soop M, Spinelli A. What is at the cutting edge of IBD? Proceedings of the European Crohn’s and Colitis Organisation 2018 Congress from a surgical perspective. Dis Colon Rectum. 2018;61(8):879–882.
   PubMed Web of Science ®Google Scholar
• Antoniou SA, Antoniou GA, Koch OO, et al. Is laparoscopic ileocecal resection a safe option for Crohn’s disease? Best evidence topic. Int J Surg. 2014;12(5):22–25.
   PubMedGoogle Scholar
• Spinelli A, Carvello M. Suprapubic single port ileocaecal resection for complicated Crohn’s disease - a video vignette. Colorectal Dis. 2017;19(10):946.
   PubMed Web of Science ®Google Scholar
• Carvello M, de Groof EJ, de Buck van Overstraeten A, et al. Single port laparoscopic ileocaecal resection for Crohn’s disease: a multicentre comparison with multi-port laparoscopy. Colorectal Dis. 2018;20(1):53–58.
   PubMed Web of Science ®Google Scholar
• Michelassi F. Crohn’s recurrence after intestinal resection and anastomosis. Dig Dis Sci. 2014;59(7):1352–1353.
   PubMed Web of Science ®Google Scholar
• Feng JS, Li JY, Yang Z, et al. Stapled side-to-side anastomosis might be benefit in intestinal resection for Crohn’s disease: A systematic review and network meta-analysis. Medicine (Baltimore). 2018;97(15):e0315.
   PubMed Web of Science ®Google Scholar
• Gajendran M, Bauer AJ, Buchholz BM, et al. Ileocecal anastomosis type significantly influences long-term functional status, quality of life, and healthcare utilization in postoperative Crohn’s disease patients independent of inflammation recurrence. Am J Gastroenterol. 2018;113(4):576–583.
   PubMed Web of Science ®Google Scholar
• Kono T, Ashida T, Ebisawa Y, et al. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn’s disease. Dis Colon Rectum. 2011;54(5):586–592.
   PubMed Web of Science ®Google Scholar
• Kono T, Fichera A, Maeda K, et al. Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn’s disease: an international multicenter study. J Gastrointest Surg. 2016;20(4):783–790.
   PubMed Web of Science ®Google Scholar
• Luglio G, Rispo A, Imperatore N, et al. Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: the SuPREMe-CD study - a randomized clinical trial. Ann Surg. 2020;272(2):210–217.
   PubMed Web of Science ®Google Scholar
• Coffey JC, O’Leary DP, Kiernan MG, et al. The mesentery in Crohn’s disease: friend or foe? Curr Opin Gastroenterol. 2016;32(4):267–273.
   PubMed Web of Science ®Google Scholar
• Wickramasinghe D, Warusavitarne J. The role of the mesentery in reducing recurrence after surgery in Crohn’s disease. Updates Surg. 2019;71(1):11–12.
   PubMed Web of Science ®Google Scholar
• Coffey CJ, Kiernan MG, Sahebally SM, et al. Inclusion of the mesentery in ileocolic resection for Crohn’s disease is associated with reduced surgical recurrence. J Crohns Colitis. 12(10): 1139–1150. 2018.
   PubMedGoogle Scholar
• Rivera ED, Coffey JC, Walsh D, et al. The mesentery, systemic inflammation, and Crohn’s disease. Inflamm Bowel Dis. 2019;25(2):226–234.
   PubMed Web of Science ®Google Scholar
• Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 224(4): 563–571. 1996.
   PubMed Web of Science ®Google Scholar
• Celentano V, O’Leary DP, Caiazzo A, et al. Longer small bowel segments are resected in emergency surgery for ileocaecal Crohn’s disease with a higher ileostomy and complication rate. Tech Coloproctol. 2019;23(11):1085–1091.
   PubMed Web of Science ®Google Scholar
• Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218–1224.
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. a prospective multicentre study of 121 cases. The Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35(2):231–235.
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Diagnosis and monitoring of postoperative recurrence in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2015;9(1):55–66.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 99(4): 956–963. 1990.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Bamba T, Umegae S, et al. The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn’s disease: a 5-year prospective cohort study. United European Gastroenterol J. 2013;1(4):294–298.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Dignass A, Danese S, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11(2):135–149.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–1621.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856–861.
   PubMed Web of Science ®Google Scholar
• Doherty GA, Bennett GC, Cheifetz AS, et al. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn’s disease. Aliment Pharmacol Ther. 2010;31(8):802–809.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology. 2004;127(3):730–740.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127(3):723–729.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008;135(4):1123–1129.
   PubMed Web of Science ®Google Scholar
• Mowat C, Arnott I, Cahill A, TOPPIC Study Group, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2016;1(4):273–282.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 136(2): 441–450. 2009.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617–1623.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: an open-label pilot study. J Crohns Colitis. 2013;7(12):e623–629.
   PubMedGoogle Scholar
• Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731–1742.
   PubMed Web of Science ®Google Scholar
• De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther. 2015;42(7):867–879.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 150(7): 1568–1578. 2016.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104(8):2089–2096.
   PubMed Web of Science ®Google Scholar
• Kotze PG, Yamamoto T, Danese S, et al. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for Crohn’s disease: results from the MULTIPER database. J Crohns Colitis. 2015;9(7):541–547.
   PubMed Web of Science ®Google Scholar
• Cañete F, Mañosa M, Casanova MJ, et al. Adalimumab or infliximab for the prevention of early postoperative recurrence of Crohn disease: results from the ENEIDA registry. Inflamm Bowel Dis. 2019;25(11):1862–1870.
   PubMed Web of Science ®Google Scholar
• Yamada A, Komaki Y, Patel N, et al. The use of vedolizumab in preventing postoperative recurrence of Crohn’s disease. Inflamm Bowel Dis. 2018;24(3):502–509.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ma T, Chen YF, et al. Biologics for the prevention of postoperative Crohn’s disease recurrence: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(5):637–649.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Mao R, Chen BL, et al. Systematic review with meta-analysis of prospective studies: anti-tumour necrosis factor for prevention of postoperative Crohn’s disease recurrence. J Crohns Colitis. 2015;9(10):918–927.
   PubMed Web of Science ®Google Scholar
• Carla-Moreau A, Paul S, Roblin X, et al. Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Dig Liver Dis. 2015;47(3):191–196.
   PubMedGoogle Scholar
• Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1):64–76.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ye X, Wu Q, et al. A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn’s disease. Int J Surg. 2014;12(5):516–522.
   PubMed Web of Science ®Google Scholar
• Bakouny Z, Yared F, El Rassy E, et al. Comparative efficacy of anti-TNF therapies for the prevention of postoperative recurrence of Crohn’s disease: a systematic review and network meta-analysis of prospective trials. J Clin Gastroenterol. 2019;53(6):409–417.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm Bowel Dis. 2009;15(10):1460–1466.
   PubMed Web of Science ®Google Scholar
• De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 385(9976): 1406–1417. 2015.
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Allen PB, et al. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35(6):625–633.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: a prospective pilot study. United European Gastroenterol J. 2013;1(5):368–374.
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148(5):938–947.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110(6):865–872.
   PubMed Web of Science ®Google Scholar